Business Context and Reporting Period
Company: Gossamer Bio, Inc. (GOSS)
Filing Type: Form 8-K (Current Report)
Report Date: March 17, 2026
Reporting Period: Quarter and fiscal year ended December 31, 2025
This filing serves as a notification that the Company issued a press release on March 17, 2026, detailing its financial results for the specified period. The full text of the press release is attached as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text acts as a cover document and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1), which is not included in the source text provided for analysis.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. It only confirms the issuance of results for the quarter and fiscal year ended December 31, 2025.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. The document explicitly states that the information in the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 17, 2026) for actual financial figures, as they are absent from the 8-K cover text.
- Verify the Company's cash runway and burn rate given the biotech sector context, as liquidity details are not in this summary.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm the status of the Company's emerging growth company election, as the checkmark in the source text is empty.